The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are…
The immune-stimulating agent, Opdivo® (nivolumab), appears to significantly improve overall survival among patients with advanced stomach cancer for which no…
The immunotherapy agent, Opdivo (nivolumab), did not demonstrate an improvement in delaying cancer progression compared to treatment with chemotherapy among…
The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo (nivolumab) for the treatment of advanced…
Non-partisan survey reveals what Americans would like from their healthcare system. Read results of the survey here: http://www.aimedalliance.org/wp-content/uploads/2016/12/Aimed-Alliance-Principles-for-U.S.-Health-Care-Poll.pdf
The United States Food and Drug Administration (FDA) has approved the agent Zejula (niraparib) for the treatment of recurrent ovarian,…
The new chemotherapy combination consisting of docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) is now considered the new standard of care for…
According to results from the MPN Landmark survey, myeloproliferative neoplasms (MPN) negatively affect the quality of life and overall health…
According to the latest report recently published by the Centers for Disease Control (CDC), cancer remains the second-leading cause of…
A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing…